Crohn's Disease with Gastric Involvement: A Case Report
Article Sidebar
Main Article Content
Abstract
Inflammatory bowel disease (IBD) encompasses acute or chronic inflammatory processes affecting the gastrointestinal tract, primarily comprising Crohn’s disease (CD) and ulcerative colitis (UC). CD is a transmural and recurrent condition that can affect any segment of the gastrointestinal tract, with gastric involvement being rare, occurring in less than 5% of cases. This report aims to describe a rare case of Crohn’s disease with exclusive gastric manifestation, highlighting the diagnostic challenges and therapeutic strategies employed. A comprehensive clinical and laboratory investigation was conducted, including outpatient interview, laboratory tests, upper gastrointestinal endoscopy, and computed tomography. The findings were analyzed to rule out other diseases with similar symptoms. The diagnosis of Crohn’s disease confined to the stomach was confirmed in a patient whose only complaint was nausea. The treatment was managed clinically and pharmacologically, with no indication for surgical intervention. During follow-up, up to the time of this report, the patient remained free of relapses or complications. Therefore, gastric Crohn’s disease is a rare and diagnostically challenging condition that requires a multidisciplinary approach to exclude other pathologies. Appropriate clinical management allowed disease control and the avoidance of complications, underscoring the importance of early diagnosis and continuous follow-up.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Oli AK, Maidur RN, Hurkadli PS, Javalgi AP, Javaregowda PK, Goni M. Incidence of inflammator bowel disease: a single centre retrospective study. Arq Gastroenterol. 2022 Jul-Sep;59(3).
Richard N, Savoye G, Leboutte M, Amamou A, Ghosh S, Marion-Letellier R. Crohn's disease: Why the ileum? World J Gas-troenterol. 2023 Jun 7;29(21):3222. doi:10.3748/wjg.v29.i21.3222.
Sella GV, Watanabe HK, Silva DW, Silva DR, Munhos VFF. Doença de Crohn com acometimento exclusivo gástrico, uma forma rara de manifestação: relato de caso. Rev Med Residente. 2013;15(4). Available from: https://crmpr.org.br/publicacoes/cientificas/index.php/revista-do-medico-residente/article/view/517. Accessed May 5, 2023.
Grupo de assistência multidisciplinar em estomias e doença inflamatória intestinal - GAMEDII. Retocolite Ulcerativa. 2019. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/lis-LISBR1.1-46451. Accessed Oct 1, 2023.
Magalhães FCB, Lima EM, Carpentieri-Primo P, Barreto MM, Rodrigues RS, Parente DB. Crohn’s disease: review and stand-ardization of nomenclature. Radiol Bras. 2023 Mar-Apr;56(2).
Greer JB, Regueiro MD. Pathophysiology and diagnosis of ulcerative colitis and Crohn disease. Hamilton (ON): Decker Intellectual Properties Inc.; 2015.
Ministério da Saúde (BR). Protocolo clínico e diretrizes terapêuticas - doença de Crohn. Portaria Nº 711, de 17 de Dezembro de 2010. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/sas/2010/prt0711_17_12_2010.html. Accessed Apr 21, 2023.
Sociedade Brasileira de Coloproctologia (SBCP). Doença de Crohn. Folhetos informativos. 2009. Available from: https://sbcp.org.br/pdfs/publico/crohn.pdf. Accessed Apr 21, 2023.
Frances D, Monahan F, Sharon A. Problemas do intestino. In: Monahan F, Sands JK, Neighbors M, Marek JF, Green CJ, editors. Enfermagem médico-cirúrgica: perspectivas de saúde e doença. 8th ed. Loures, Portugal: Lusodidacta; 2010.
Teixeira MG. Tratamento cirúrgico da doença de Crohn [thesis]. São Paulo: Universidade de São Paulo; 2000. Available from: https://repositorio.usp.br/item/001219829. Accessed Apr 22, 2023.
Garcia NM, Cohen NA, Rubin DT. Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 Dec 12. doi:10.1002/ueg2.12336. Available from: https://pubmed.ncbi.nlm.nih.gov/36507876/. Accessed Aug 3, 2023.
Imbrizi M, Baima JP, Azevedo MFC, Andrade AR, Queiroz NSF, Chebli JMF, et al. Second Brazilian consensus on the man-agement of Crohn’s disease in adults: a consensus of the Brazilian Organization for Crohn’s Disease and Colitis (GEDIIB). Arq Gastroenterol. 2022;59(Suppl 1).
Head K, Jurenka JS. Inflammatory bowel disease. Part II: Crohn's disease--pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2004 Dec;9(4):360-401. PMID: 15656711.
Cantarelli BCF, Oliveira RS, Alves AMA, Ribeiro BJ, Velloni F, D’ippolito G. Avaliação da atividade inflamatória da doença de Crohn por métodos seccionais de imagem. Radiol Bras. 2020 Jan-Feb;53(1):38–46.
Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63:558–65.
Romero-Mascarell C, et al. Fecal calprotectin for small bowel Crohn’s disease: Is it a cutoff issue? Diagnostics (Basel). 2022;12(9):2226.
Semedo F, Quintaneiro C, Silva RS, Loureiro L, Dias R, Guedes F, Pereira A. Linfoma intestinal de células T e doença celíaca. GE J Port Gastrenterol. 2013;20(3):123-127.
da Silva FAR. Análise transcricional total identifica marcadores de vias de linfócitos B, T e plasmócitos no tecido adiposo mesenterial de pacientes com doença de Crohn [dissertation]. [S.l.]: [s.n.]; 2019.
Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644-653. doi:10.1016/j.cgh.2008.03.014.
Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute tech-nical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1464-78.e785. doi:10.1053/j.gastro.2013.10.046.
Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370-1377. doi:10.1016/j.cgh.2008.06.007.
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528. doi:10.1056/NEJMoa1203572.
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113(4):481-517. doi:10.1038/ajg.2018.27.
Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022.